Healthcare

💊 Rapamycin vs. Exercise: A controlled trial found the longevity drug blunted physical gains in older adults, raising urgent questions about combining mTOR inhibition with exercise-based longevity protocols. 🧫 Harvard Pinpoints How a Gut Bacterium Triggers Depression: Morganella morganii produces an inflammation-triggering molecule when interacting with a common pollutant, providing the first mechanistic explanation for the gut-brain-depression link. 🤖 NVIDIA and Lilly Commit $1B to AI Drug Discovery Infrastructure: The San Francisco co-innovation lab marks one of the largest AI-pharma investments ever, aiming to compress the full drug development value chain with agentic AI systems. 🦠 Roseburia Bacteria Linked to 29% Greater Grip Strength in Older Adults: The gut species declines sharply with age and its restoration in mice produced a 30% strength gain, opening a new probiotic angle on sarcopenia prevention. 🧬 T Cell Senescence Drives 40% of Immune Gene Expression Changes: Senescence, not chronological age, is the primary epigenomic driver of immune aging, suggesting senolytics could restore immune function independent of broader biological age reversal strategies.

🧬 SuperAgers Reveal the Biology of Exceptional Brain Longevity — Adults over 80 with 50-year-old memory function produce twice as many new hippocampal neurons as peers, with resistance and resilience to Alzheimer's pathology both playing a role in cognitive fate. 🤖 Novo Nordisk and Insilico Advance the AI Drug Discovery Era — Novo's sweeping OpenAI partnership and Insilico's new TargetPro-TargetBench framework signal that AI is moving from research novelty to core pharmaceutical operational infrastructure. ☕ Coffee Rewires the Gut Microbiome and Modifies Brain Function — A Nature Communications human trial confirms habitual coffee intake shifts microbial communities and alters cognition and mood through gut-brain axis pathways distinct from caffeine's direct neurological effects. 🔬 Immature Neuron Behavior, Not Quantity, Determines Alzheimer's Resilience — Netherlands researchers found that the 30% of Alzheimer's patients who never develop dementia have immature neurons that activate protective programs, opening a new class of therapeutic targets beyond amyloid clearance. 🧬 Geroscience Proposes Preventing Multiple Diseases by Targeting Aging Itself — ACS Pharmacology researchers argue that senolytic, mTOR-inhibition, and NAD+ interventions targeting biological aging upstream could delay several chronic conditions simultaneously, calling for regulatory reform to support multimorbidity prevention.